COYA Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
243.7K
-2.9%
251.1K
-93.7%
4.0M
+11.1%
3.6M
+2078.4%
163.6K
Cost of Revenue
0
0
0
0
0
Gross Profit
243.7K
-2.9%
251.1K
-93.7%
4.0M
+11.1%
3.6M
+2078.4%
163.6K
Operating Expenses
7.3M
-7.6%
7.9M
-21.0%
10.0M
+66.6%
6.0M
-8.8%
6.6M
R&D
5.0M
+22.5%
4.1M
-38.8%
6.7M
+95.6%
3.4M
-6.3%
3.7M
SG&A
2.3M
-40.4%
3.8M
+15.7%
3.3M
+27.9%
2.6M
-12.1%
2.9M
Operating Income
-7046988
+7.8%
-7640217
-26.7%
-6030888
-147.9%
-2432897
+62.1%
-6414518
EBITDA
-7044181
+7.8%
-7637410
-26.8%
-6024047
-148.3%
-2426057
+62.1%
-6407678
Net Income
-6638260
+7.9%
-7206990
-26.2%
-5708542
-169.8%
-2115831
+65.3%
-6094977
EPS (Basic)
$-0.28
+12.5%
$-0.32
+5.9%
$-0.34
-161.5%
$-0.13
+63.9%
$-0.36
EPS (Diluted)
$-0.28
+12.5%
$-0.32
+5.9%
$-0.34
-161.5%
$-0.13
+63.9%
$-0.36
Shares (Diluted)
23.5M
+3.6%
22.6M
+35.2%
16.7M
+0.1%
16.7M
+0.0%
16.7M
Coya Therapeutics (COYA) โ€” Financials